Your browser doesn't support javascript.
loading
A Phase Ib/II, open-label, multicenter study of INC280 (capmatinib) alone and in combination with buparlisib (BKM120) in adult patients with recurrent glioblastoma.
van den Bent, Martin; Azaro, Analia; De Vos, Filip; Sepulveda, Juan; Yung, W K Alfred; Wen, Patrick Y; Lassman, Andrew B; Joerger, Markus; Tabatabai, Ghazaleh; Rodon, Jordi; Tiedt, Ralph; Zhao, Sylvia; Kirsilae, Tiina; Cheng, Yi; Vicente, Sergio; Balbin, O Alejandro; Zhang, Hefei; Wick, Wolfgang.
Afiliação
  • van den Bent M; Erasmus University Medical Center (MC) Cancer Institute, Rotterdam, The Netherlands. m.vandenbent@erasmusmc.nl.
  • Azaro A; Molecular Therapeutics Research Unit (UITM), Department of Medical Oncology, Vall d'Hebron University Hospital, Barcelona, Spain.
  • De Vos F; University Medical Center Utrecht, Utrecht, The Netherlands.
  • Sepulveda J; Hospital Universitario, 12 de Octubre, Madrid, Spain.
  • Yung WKA; MD Anderson Cancer Center, Houston, TX, USA.
  • Wen PY; Center for Neuro-Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.
  • Lassman AB; Department of Neurology and Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, NY, USA.
  • Joerger M; Cantonal Hospital, St. Gallen, Switzerland.
  • Tabatabai G; Interdisciplinary Division of Neuro-Oncology, Center for CNS Tumors, Comprehensive Cancer Center, University Hospital Tübingen, Hertie Institute for Clinical Brain Research & Eberhard Karls University Tübingen, German Cancer Consortium (DKTK), DKFZ Partner Site Tübingen, Tübingen, Germany.
  • Rodon J; MD Anderson Cancer Center, Houston, TX, USA.
  • Tiedt R; Novartis Pharma AG, Basel, Switzerland.
  • Zhao S; Novartis Institutes for Biomedical Research (China), Shanghai, China.
  • Kirsilae T; Novartis Pharma AG, Basel, Switzerland.
  • Cheng Y; Novartis Institutes for Biomedical Research (China), Shanghai, China.
  • Vicente S; Novartis Pharma AG, Basel, Switzerland.
  • Balbin OA; Novartis Institutes for Biomedical Research (United States), Boston, MA, USA.
  • Zhang H; Novartis Institutes for Biomedical Research (China), Shanghai, China.
  • Wick W; Clinical Cooperation Unit Neurooncology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), and Neurology Clinic and National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany.
J Neurooncol ; 146(1): 79-89, 2020 Jan.
Article em En | MEDLINE | ID: mdl-31776899
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Encefálicas / Protocolos de Quimioterapia Combinada Antineoplásica / Glioblastoma / Recidiva Local de Neoplasia Idioma: En Ano de publicação: 2020 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Encefálicas / Protocolos de Quimioterapia Combinada Antineoplásica / Glioblastoma / Recidiva Local de Neoplasia Idioma: En Ano de publicação: 2020 Tipo de documento: Article